The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Recurrence of high‐risk bladder cancer: A population‐based analysis
Open accessAbstract
BACKGROUND: Patients with bladder cancer are apt to develop multiple recurrences that require intervention. The recurrence, progression, and bladder cancer–related mortality rates were examined in a cohort of individuals with high‐grade non–muscle‐invasive bladder cancer. METHODS: Using linked Surveillance, Epidemiology, and End Results (SEER)‐Medicare data, subjects were identified who had a diagnosis of high‐grade, non–muscle‐invasive disease in 1992 to 2002 and who were followed until 2007. Multivariate competing‐risks regression analyses were then used to examine recurrence, progression, and bladder cancer–related mortality rates. RESULTS: Of 7410 subjects, 2897 (39.1%) experienced a recurrence without progression, 2449 (33.0%) experienced disease progression, of whom 981 succumbed to bladder cancer. Using competing‐risks regression analysis, the 10‐year recurrence, progression, and bladder cancer–related mortality rates were found to be 74.3%, 33.3%, and 12.3%, respectively. Stage T1 was the only variable associated with a higher rate of recurrence. Women, black race, undifferentiated grade, and stage Tis and T1 were associated with a higher risk of progression and mortality. Advanced age (≥ 70) was associated with a higher risk of bladder cancer–related mortality. CONCLUSIONS: Nearly three‐fourths of patients diagnosed with high‐risk bladder cancer will recur, progress, or die within 10 years of their diagnosis. Even though most patients do not die of bladder cancer, the vast majority endures the morbidity of recurrence and progression of their cancer. Increasing efforts should be made to offer patients intravesical therapy with the goal of minimizing the incidence of recurrences. Furthermore, the high recurrence rate seen during the first 2 years of diagnosis warrants an intense surveillance schedule. Cancer 2013;119:3219–3227. © 2013 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,781
Sylvester, R. J., van der Meijden, A. P. M., Oosterlinck, W., Witjes, J. A., Bouffioux, C., Denis, L., Newling, D. W. W., & Kurth, K. (2006) · European Urology · doi:10.1016/j.eururo.2005.12.031 · Cited by 3,013
Development of a comorbidity index using physician claims data
Klabunde, C. N., Potosky, A. L., Legler, J. M., & Warren, J. L. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00256-0 · Cited by 1,845
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · PubMed · doi:10.1097/01.mlr.0000020942.47004.03 · Cited by 1,714
Superficial Bladder Cancer: Progression and Recurrence
Heney, N. M., Ahmed, S., Flanagan, M. J., Frable, W., Corder, M. P., Hafermann, M. D., Hawkins, I. R., & For National Bladder Cancer Collaborative Group A S002253471751695X-1bb6d6502e02ba4ea1210f9f5bd6022d George R. Prout The principal investigators and institutions that contributed to the study are, M. G. H. (1983) · Journal of Urology · doi:10.1016/s0022-5347(17)51695-x · Cited by 924
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · Medical Care · doi:10.1097/00005650-200208001-00002 · Cited by 772
Sarkis, A. S., Dalbagni, G. M., Cordon‐Cardo, C., Zhang, Z., Sheinfeld, J., Fair, W. R., Herr, H. W., & Reuter, V. E. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.1.53 · Cited by 517
Bach, P. B., Guadagnoli, E., Schrag, D., Schussler, N., & Warren, J. L. (2002) · Medical Care · doi:10.1097/00005650-200208001-00003 · Cited by 245
Gore, J. L., Lai, J., Setodji, C. M., Litwin, M. S., & Saigal, C. S. (2009) · Cancer · doi:10.1002/cncr.24052 · Cited by 239
Self-citationDefining Optimal Therapy for Muscle Invasive Bladder Cancer
Herr, H. W., Dotan, Z., Donat, S. M., & Bajorin, D. F. (2007) · Journal of Urology · doi:10.1016/j.juro.2006.09.027 · Cited by 226
Fedeli, U., Fedewa, S. A., & Ward, E. M. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.09.015 · Cited by 187
Tumour progression and survival in patients with T1G3 bladder tumours: 15‐year outcome
HERR, H. W. (1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.00431.x · Cited by 171
Compliance with guidelines for patients with bladder cancer: Variation in the delivery of care
Chamie, K., Saigal, C. S., Lai, J., Hanley, J. M., Setodji, C. M., Konety, B. R., Litwin, M. S., & The Urologic Diseases in America Project (2011) · Cancer · doi:10.1002/cncr.26198 · Cited by 159
Self-citationJoudi, F. N., Smith, B. J., O’Donnell, M. A., & Konety, B. R. (2006) · The Journal of Urology · doi:10.1016/s0022-5347(05)00973-0 · Cited by 154
Self-citationTHE REGIONALIZATION OF RADICAL CYSTECTOMY TO SPECIFIC MEDICAL CENTERS
Hollenbeck, B. K., Taub, D. A., Miller, D. C., Dunn, R. L., Montie, J. E., & Wei, J. T. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000173632.58991.a7 · Cited by 89
Lambert, E. H., Pierorazio, P. M., Olsson, C. A., Benson, M. C., McKiernan, J. M., & Poon, S. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.06912.x · Cited by 87
Quality of care in patients with bladder cancer
Chamie, K., Saigal, C. S., Lai, J., Hanley, J. M., Setodji, C. M., Konety, B. R., Litwin, M. S., & the Urologic Diseases in America Project (2011) · Cancer · doi:10.1002/cncr.26402 · Cited by 74
Self-citationEstablishment of a Urological Surgery Quality Collaborative
Miller, D. C., Murtagh, D. S., Suh, R. S., Knapp, P. M., Dunn, R. L., & Montie, J. E. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.08.015 · Cited by 53
Understanding bladder cancer death: Tumor biology versus physician practice
Morris, D. S., Weizer, A. Z., Ye, Z., Dunn, R. L., Montie, J. E., & Hollenbeck, B. K. (2009) · Cancer · doi:10.1002/cncr.24136 · Cited by 38
Cited by
Cancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597
Pietzak, E. J., Bagrodia, A., Cha, E. K., Drill, E. N., Iyer, G., Isharwal, S., Ostrovnaya, I., Baez, P., Li, Q., Berger, M. F., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.05.032 · Cited by 373
Yu, L., Li, Z., Mei, H., Li, W., Chen, D., Liu, L., Zhang, Z., Sun, Y., Song, F., Chen, W., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1248 · Cited by 113
Metadata
- Authors
- Chamie, K., Litwin, M. S., Bassett, J. C., Daskivich, T. J., Lai, J., Hanley, J. M., Konety, B. R., Saigal, C. S., & the Urologic Diseases in America Project
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2013-06-04
- Volume
- 119
- Issue
- 17
- Pages
- 3219-3227
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1711618159
- Cited by
- 352
- References
- 21
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.